Learn more about UC TechAlerts – Subscribe to categories and get notified of new UC technologies

Browse Category: Medical > Disease: Cardiovascular and Circulatory System

Categories

[Search within category]

A Novel Method to Generate Specific and Permanent Macromolecular Covalent Inhibitors

UCSF researchers have invented a novel method to generate covalent macromolecular inhibitors. This strategy allows a peptide inhibitor to bind to its target protein specifically and irreversibly through proximity-enabled bioreactivity.

Omnidirectional MRI Catheter Resonator for Interventional Procedures

This invention describes an orientation-independent device that can create bright and highly localized signal enhancement during magnetic resonance imaging.

Repurposing Dabuzalgron to Prevent and Treat Cardiomyopathy and Heart Failure

Using an alpha-1A-adrengic receptor agonist, dabuzalgron, as a therapeutic treatment for cardiomyopathy and heart failure.

Multi-purpose Delivery Catheter for Injecting a Substrate into a Tissue

A catheter with a retractable needle along a camera, a balloon, and/or a vacuum port to inject material or a device into a tissue of a patient

Measurement Of Blood Flow Dynamics With X-Ray Computed Tomography: Dynamic Ct Angiography

This invention identifies a method to accurately measure flow dynamics, such as velocity and volume, from Computed Tomography scans of blood vessels in a patient.

SALT-SPARING UREA TRANSPORT INHIBITOR DIURETICS FOR TREATMENT OF CARDIOVASCULAR AND RENAL DISORDERS

Therapeutic inhibitors of Urea Transporter A (UT-A) as highly effective diuretics with reduced risk of cardiac and neurological side effects for treatment of cardiovascular and renal disorders

PRO- RESOLVING MEDIATORS AND DEVICES FOR THERAPEUTIC MODULATION OF BLOOD VESSEL HEALING

This invention consists of the use of a novel class(es) of anti-inflammatory and pro-resolving mediators derived from ω-3 polyunsaturated fatty acids, as well as devices designed to deliver these mediators directly to blood vessel for therapeutic modulation of blood vessel healing.

Novel Peptide-modified Thermo-reversible Methylcellulose for Treatment of Chronic Myocardial Ischemic Damage

This invention consists of a novel peptide-modified thermo-reversible methylcellulose (MC) that has the therapeutic potential to repair chronic ischemic cardiomyopathy.

AUTOLOGOUS CARDIAC STEM CELL THERAPY FOR HEART FAILURE

Over 5 million Americans currently suffer with congestive heart failure and despite aggressive medical therapies targeted to treat this disease; the outlook for these patients remains grim, with estimated mortalities of 33% and 50% at 1 and 5 years, respectively. Congestive heart failure (CHF) remains a significant unmet need in the global medical community. A treatment option for CHF by cellular transplantation of stem cells is a developing research area. This approach has been studied using fetal cardiomyocytes, adult skeletal muscle cells, autologous bone marrow-derived mesenchymal stem cells, cardiac progenitor (CP) cells, and cardiomyocytes derived from embryonic stem cells. However, current studies have yielded modest results in reducing infarct size and scar tissue. Furthermore, the necrotic/apoptotic loss of the vast majority of donor cells within days after transplantation is a major drawback. 

A Small Molecule Alpha-1-Adrenergic Receptor Agonist For Treating and Preventing Heart Muscle Diseases

Anthracyclines are the most commonly prescribed chemotherapeutic agent for their effectiveness in treating cancer.  However use of anthracyclines can have the severe, adverse effect of cardiac toxicity leading to cardiomyopathy and clinical heart failure.  Currently available medications to counteract anthracycline-induced cardiotoxicity either do so at the cost of anti-tumor activity, or there is insufficient clinical trial data to support their efficacy in preventing cardiotoxicity.  Thus widespread use of these compounds is limited.    There is a clinical need for a pharmaceutical compound that can prevent and/or treat the cardiac side effects of anthracyclines while maintaining their anti-tumor activity.

A Novel Therapeutic Approach After a Heart Attack

Myocardial infarction (MI) is a leading cause of cardiovascular diseases worldwide.  There are five million people that suffer from heart failure in the United States alone at a cost of $30 billion per year.  MI often results in scar formation and death of contracting heart muscle cells (cardiomyocytes).  The subsequent scarring of cardiomyocytes will permanently damage a patient's heart, leading to a life threatening heart rate disorder (arrhythmia).  Despite therapeutic advances in heart disease, there are currently no treatments that can replace scarred cardiomyocytes with functional ones.

Methodology to Measure Transvalvular Energy Loss Using Doppler Echocardiography

In patients with stenosed heart valves, hemodynamic performance of the heart valve is routinely assessed to determine risk stratification and timing of intervention. Hemodynamic performance is also used to evaluate the success of a valve transplant and monitor the performance of the valve over time. Current measures of hemodynamic performance include measures of transvalvular pressure gradient, effective orifice area, and blood flow velocity.  These common criteria only allow assessment of forward flow and do not take into account paravalvular leak and paravalvular regurgitation (backward flow). Leak and regurgitation are commonly seen in stenosed valves, deformed prostheses, and particularly in transcatheter valves. Assessment of valvular hemodynamics during both forward and backward flow would improve risk stratification of patients and timing of interventions.      Valve hemodynamics during both forward and backward flow can be assessed by measuring energy loss. Until now, routine clinical application of energy loss measurement has been hindered by its invasive nature and a lack of simple tools to obtain the data. Energy loss measurement currently requires catheterization and placement of pressure transducers inside the artery on opposite sides of the valve in question.  A non-invasive and simple way to measure energy loss would provide clinicians with a tool to improve assessment of hemodynamics and improve patient care.     

Novel Arm Board Design For Catheterization Labs

In the U.S. alone, four million cardiac catheterization procedures are performed every year. Percutaneous catheterization is used in the clinics to both diagnose and treat cardiovascular diseases by introducing a catheter into an artery and guiding it towards the heart where various procedures are performed, such as angioplasty, stent placement, imaging and cardiac measurements. These procedures take place in a specialized catheterization laboratory ("cath lab") while a patient is lying on a radiolucent table. An X-ray machine allows the physician to visualize the catheter throughout the process. Until recently, percutaneous catheterizations were primarily performed by inserting a catheter through the femoral artery located in the upper thigh, however this can lead to complications. As a result, the use of transradial catheterization, where a catheter is guided through the radial artery in the wrist, has grown. During the transradial intervention, the arm must be placed on an arm board because the cath table is, out of necessity, too narrow to accommodate this.  Transradial catheterization has several benefits in comparison to the traditional femoral artery approach: 1. Fewer complications - less bleeding and therefore less chance that a blood transfusion is needed. 2. Faster procedure - results in greater patient turnover and increased revenue for facilities, including reduction in nurse overtime pay. 3. Quicker recovery - same day release, rather than overnight stays. 4. Greater patient comfort - no need for immobilization, back pain and time to ambulation are reduced. The use of transradial interventions is increasing in the U.S. and is the dominant procedure in many European and Asian countries.

A safe and reliable device for endovascular biopsy

UCSF inventors have developed a safe endovascular biopsy device for extraction of endothelial cells from the blood vessel wall.

Improved Transcatheter Aortic Valve for Valve-in-Valve Implantation

UCSF investigators have developed a new percutaneous prosthetic aortic valve that can be used for valve-in-valve replacement of either native or prosthetic aortic valves. The design allows for supravalvular placement of the prosthetic valve.  Advantages include reduced paravalvular leak, reduced energy loss and improved hemodynamics regardless of the calcification level of the diseased valve.

Prognostic Biomarker for Myocardial Tissue Health in Patients with Heart Failure

UCSF researchers have discovered a novel prognostic biomarker of heart tissue health for assessment of risk of cardiac mortality and the need for a heart transplant vs. LVAD implantation in end stage heart failure.  The test would also help clinicians monitor improvement after LVAD implantation. 

Small Molecule Therapy for Obesity, Dyslipidemia, and Metabolic Disease

  BACKGROUND: Cardiovascular disorders are leading causes of death worldwide and products have been developed to treat several of their addressable risk factors. Today’s market for anti-hypertensive agents is $35 billion and dyslipidemia treatments is $30 billion. While these therapies have been effective in the majority of patients in lowering blood pressure and LDL (low-density lipoprotein), they do not address other major cardiovascular risk factors such as obesity, liproprotein (a), HDL (high-density lipoprotein), and triglyceride levels. There is an unmet need for new agents that can be used alone or in combination with existing therapies to address these more elusive risk factors.   DESCRIPTION: Researchers at University of California San Francisco and Oregon Health Sciences University have discovered a new class of thyroid hormone metabolites. The most potent of these, 3-iodothyronamine, has been shown in animal studies to completely switch fuel utilization away from carbohydrates and toward lipids. In single dose hamster studies this lipid-burning effect was sustained for 24 hours, several hours after the compound had been excreted. Further studies showed both reduced LDL and significant weight loss that was selective for fat mass vs. lean mass. 3-iodothyronamine is known to be an endogenous chemical derivative of thyroid hormone, a key hormone in regulating basal metabolic rate, protein synthesis, bone growth, neuronal maturation, and metabolism of lipids and carbohydrates.

SOFTWARE TO PREDICT CLINICAL BENEFIT OF PACEMAKER PLACEMENT THROUGH VENTRICULAR SYNCHRONY ASSESSMENT

Patients suffering from moderate to severe cardiac failure can enjoy substantial improvements in quality of life and survival, when provided with cardiac resynchronization therapy (CRT). However, this treatment has a 30% failure rate due in part to difficulties in characterizing intraventricular synchrony. Improvements in methodology could lead to appropriate patient selection and improved pacemaker positioning, resulting in enhanced therapeutic effectiveness. To redress these problems, UCSF researchers have developed software that permits the visualization and quantification of relevant parameters using a number of different imaging tools. Their novel method employs first harmonic imaging to the blood pool study, yielding a quantitative basis for treatment and evaluation.

A NEW MOUSE MODEL FOR THE STUDY OF OBESITY

Obesity, an epidemic problem in the US population, has been linked to several major medical problems, including diabetes, stroke, heart disease, high blood pressure and even cancer. Determinants of obesity are complex and genetics account for approximately 25-40% of cases. Although there is great emphasis on discovering the underlying genetic basis for predisposition to obesity, much remains unknown. As a result, there does not yet exist a safe, effective and proven therapy for treatment of obesity.UCSF investigators have developed a new mouse model of obesity. They have generated a transgenic mouse with a hypomorphic allele of the receptor tyrosine kinase TrkB. TrkB is expressed throughout the brain, including the hypothalamus, the center known to control eating behavior. These transgenic mice express TrkB protein at 24% of normal levels in the hypothalamus, and display a maturity onset obesity syndrome. By 12 weeks of age the mutant mice exhibit significant weight gain compared to their wildtype littermates and display hyperphagia as well as significantly increased levels of insulin and leptin in the bloodstream. A similar phenotype has been observed in mice with only one functional allele of BDNF, a ligand of the TrkB receptor (Kernie et al., EMBO J., 2000, 19:1290-1300). These phenotypes parallel those observed in human obesity, indicating that the BDNF/TrkB interaction is a potential target for the development of treatments for obesity and that the TrkB transgenic mice represent a valuable model for studying the development of obesity.

SMALL MOLECULE INHIBITORS OF THE HUMAN UREA TRANSPORTER ('UREARETICS') FOR USE AS A NOVEL DIURETIC

Volume over-load conditions, such as congestive heart failure, cirrhosis, nephrotic syndrome, and volume-sensitive hypertension are often treated with a battery of different types of diuretics, such as loop diuretics, thiazides, and K-sparing diuretics that affect different functions of the kidney.  However, some of these diuretics, particularly thiazides, cause unwanted side-effects, such as potassium imbalance or acid-base disorders.  Diuretics also have limited efficacy in some conditions (e.g., diuretic-refractory edema in congestive heart failure). Recent studies suggest that drugs designed to inhibit urea transporters (a.k.a. "urearetics") in the kidney could be used to treat water and salt imbalance disorders.  Urea transporters play a role in concentrating urea in the urine and thus affect water and salt concentrations.  One potential advantage of urearetics is that they are unlikely to cause secondary potassium imbalance or acid-base disorders.  Unfortunately, potent and specific urea transporter inhibitors have not been available.

  • Go to Page: